Indivior PLC header image

Indivior PLC

INDV

Equity

ISIN GB00BN4HT335 / Valor 121550831

LSE London Stock Exchange, SETS (2025-11-17)
GBP 23.82+2.64%

Indivior PLC
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Indivior PLC is a global specialty pharmaceutical company focused on the development, manufacture, and commercialization of innovative treatments for addiction and related mental health disorders. The company's portfolio includes a range of products designed to help individuals suffering from opioid dependence, alcohol use disorder, and other substance abuse issues. Indivior is committed to improving the lives of patients by providing access to high-quality, evidence-based medications and support services.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.10.2025):

Indivior PLC reported its financial results for the second quarter of 2025, showcasing growth in key revenue segments and raising its full-year financial guidance based on stronger-than-expected performance.

Total Revenue Growth

In Q2 2025, Indivior achieved total net revenue of $302 million, marking a 1% increase compared to Q2 2024. This growth was primarily driven by a 9% year-over-year rise in SUBLOCADE® net revenue, which reached $209 million.

SUBLOCADE® Performance

SUBLOCADE® net revenue grew by 9% year-over-year to $209 million and increased by 19% compared to Q1 2025. U.S. SUBLOCADE® specifically saw a 9% rise to $195 million from Q2 2024 and a 20% increase from Q1 2025, driven mainly by volume growth.

Financial Guidance Raised

Due to the robust performance in the first half of the year, Indivior has raised its full-year 2025 financial guidance. Total net revenue guidance was increased by $65 million, and adjusted EBITDA guidance was raised by $48 million at the midpoints of the original estimates.

Net Income and Earnings Per Share

For Q2 2025, Indivior reported a net income of $18 million and diluted earnings per share (EPS) of $0.14, a significant improvement from a net loss of $97 million and a diluted loss per share of $(0.72) in Q2 2024.

Operational Enhancements

Indivior initiated its Action Agenda to strengthen the business and generate operational momentum, focusing on expanding U.S. SUBLOCADE® revenue and simplifying the organizational structure. Additionally, the company enhanced its executive team and board of directors, and successfully delisted from the London Stock Exchange to concentrate on Nasdaq and U.S. growth.

Summarized from source with an LLMView Source

Key figures

207%1Y
43.5%3Y
281%5Y

Performance

53.7%1Y
54.3%3Y
50.8%5Y

Volatility

Market cap

3909 M

Market cap (USD)

Daily traded volume (Shares)

1,755,999

Daily traded volume (Shares)

1 day high/low

9.925 / 9.635

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Bio-Rad Laboratories, Inc. Class B
Bio-Rad Laboratories, Inc. Class B Bio-Rad Laboratories, Inc. Class B Valor: 912794
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.18%USD 310.70
Glaukos Corp
Glaukos Corp Glaukos Corp Valor: 28262610
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.81%USD 88.40
Inspire Medical Systems Inc
Inspire Medical Systems Inc Inspire Medical Systems Inc Valor: 41329373
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.71%USD 84.87
agilon health inc
agilon health inc agilon health inc Valor: 110653729
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-6.75%USD 0.54
Helen of Troy Ltd
Helen of Troy Ltd Helen of Troy Ltd Valor: 938381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.14%USD 17.55
M1 Kliniken AG
M1 Kliniken AG M1 Kliniken AG Valor: 29694419
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.71%EUR 15.54
STERIS PLC
STERIS PLC STERIS PLC Valor: 47027903
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.54%USD 257.01
Perrigo Company PLC
Perrigo Company PLC Perrigo Company PLC Valor: 22008864
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.60%USD 13.56
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-7.42%USD 3.87
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.08%USD 25.08